Under the terms of the agreement, Jacobs is providing engineering, procurement and construction management (EPCM) services to increase the site’s production capacity by 70 percent and create a second line of purification that allows for multiple drugs to be manufactured simultaneously.
Already one of the world’s largest production facilities for monoclonal antibodies from mammalian cells, the expansion project adds cell culture bioreactors to the site.
Jacobs’ services are being led from its operations in Milan, Italy.
In making the announcement, Jacobs Senior Vice President Life Sciences Robert Norfleet stated, “We look forward to partnering with Novartis on the expansion of its Huningue site. We’re proud to have this opportunity to draw on our extensive global EPCM expertise for a project that can help Novartis improve the lives of people who depend on its treatments.”
The $100 million expansion project is scheduled to be completed in four years.